■本研究评估了比格列净的临床安全性和有效性,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,2型糖尿病(T2DM)患者的血糖管理。
■我们检查了T2DM患者的随机对照试验,比较了20mg每日一次口服bexagliflozin与安慰剂治疗血糖的临床有效性和安全性,直至2023年5月28日,发表在ClinicalTrials.gov等数据库上,PubMed,Embase,科克伦图书馆此外,还评估了体重和收缩压(SBP)的下降以及糖化血红蛋白(HbA1c)相对于基线<7%的个体百分比.审查管理器5用于调查检索到的数据。
■我们涉及八个RCT。Bexagliflozin在降低HbA1c方面显着优于[最小二乘均差(LSMD)=-0.45,95%置信区间(CI=-0.55至-0.34,p<0.00001],空腹血浆糖(FPG)[LSMD=-1.37,95CI=-1.73至-1.00,p<0.00001],体重(LSMD=-1.77,95CI=-2.44至-1.10,p<0.00001),与安慰剂相比,SBP(LSMD=-4.11,95CI=-6.18至-2.03,p=0.0001)。bexagliflozin的安全性结果与安慰剂组一致。这项研究得出结论,bexagliflozin似乎是一种有希望的口服抗糖尿病药物,用于增强成年T2DM患者的血糖管理。
Bexagliflozin,一种新型降血糖药,是TheracosBio开发的一种非常有效的SGLT2抑制剂,用于管理T2DM的血糖。美国食品和药物管理局(USFDA)于2023年1月20日首次批准bexagliflozin,用于作为2型糖尿病患者生活方式改变和锻炼的辅助治疗剂。所有纳入的RCTs均研究了20mgbexagliflozin对T2DM的血糖和血糖外作用的治疗效果和安全性。Bexagliflozin20mg显着降低HbA1c,FPG(血糖效应),体重,和SBP(血糖外效应)与安慰剂组相比T2DM。安全性数据显示,bexagliflozin与安慰剂组和多尿相当,尿路感染(UTI),鼻咽炎或上呼吸道感染(URTI),低血糖,恶心,和腹泻是最常见的非严重不良反应。与安慰剂组相比,Bexagliflozin20mg似乎是一种有效的SGLT2抑制剂,可以控制T2DM患者的血糖,并具有良好的血糖外作用。
UNASSIGNED: This study assessed the clinical safety and efficacy of bexagliflozin, a sodium-glucose cotransporter 2(SGLT2) inhibitor, in managing glycemia among patients with type 2 diabetes mellitus (T2DM).
UNASSIGNED: We examined RCTs with T2DM comparing the clinical effectiveness and safety of 20 mg once daily oral dose of bexagliflozin with placebo for managing glycemia till 28 May 2023, published on databases like ClinicalTrials.gov, PubMed, Embase, and Cochrane Library. Furthermore, reduction of body weight, fasting plasma sugarr(FPG), systolic blood pressure (SBP) and the percentage of individuals who achieved glycated hemoglobin (HbA1c) of < 7% from baseline were also evaluated. The
Review Manager 5 was utilized to investigate the retrieved data.
UNASSIGNED: We involved eight RCTs. Bexagliflozin was significantly superior in reducing HbA1c[least squares mean difference(LSMD) = -0.45,95% confidence interval (CI =-0.55 to -0.34,p < 0.00001], FPG [LSMD= -1.37, 95%CI =-1.73 to -1.00, p < 0.00001], body weight (LSMD= -1.77, 95%CI =-2.44 to-1.10, p < 0.00001), and SBP(LSMD= -4.11,95%CI = -6.18 to -2.03,p = 0.0001) in comparison to placebo. The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM.
Bexagliflozin, a novel hypoglycemic agent, is an extremely effective SGLT2 inhibitor developed by TheracosBio to manage glycemia in T2DM. The United States Food and Drug Administration (USFDA) granted first approval of bexagliflozin on 20 January 2023, for usage as an adjunctive therapy agent alongside lifestyle changes and exercise in T2DM. All included RCTs have investigated the therapeutic efficacy and safety of bexagliflozin 20 mg concerning glycemic and extra-glycemic effects in T2DM. Bexagliflozin 20 mg significantly reduces HbA1c, FPG (glycemic effect), body weight, and SBP (extra-glycemic effect) compared to the placebo arm in T2DM. Safety data show that bexagliflozin was comparable to placebo arm and polyuria, urinary tract infection (UTI), nasopharyngitis or upper respiratory tract infection (URTI), hypoglycemia, nausea, and diarrhea were the most common non-serious adverse effects. Bexagliflozin 20 mg seems to be an effective SGLT2 inhibitor compared to the placebo arm to manage glycemia in patients with T2DM along with favorable extra-glycemic effects.